Search Results - "Wasko, N."

Enhanced TLR2 responses in multiple sclerosis by Fujiwara, M., Anstadt, E. J., Flynn, B., Morse, K., Ng, C., Paczkowski, P., Zhou, J., Mackay, S., Wasko, N., Nichols, F., Clark, R. B.

“…Summary The roles of the microbiome and innate immunity in the pathogenesis of multiple sclerosis (MS) remain unclear. We have previously documented abnormally…”
Get full text

Tumour-selective activity of RAS-GTP inhibition in pancreatic cancer by Wasko, Urszula N., Jiang, Jingjing, Dalton, Tanner C., Curiel-Garcia, Alvaro, Edwards, A. Cole, Wang, Yingyun, Lee, Bianca, Orlen, Margo, Tian, Sha, Stalnecker, Clint A., Drizyte-Miller, Kristina, Menard, Marie, Dilly, Julien, Sastra, Stephen A., Palermo, Carmine F., Hasselluhn, Marie C., Decker-Farrell, Amanda R., Chang, Stephanie, Jiang, Lingyan, Wei, Xing, Yang, Yu C., Helland, Ciara, Courtney, Haley, Gindin, Yevgeniy, Muonio, Karl, Zhao, Ruiping, Kemp, Samantha B., Clendenin, Cynthia, Sor, Rina, Vostrejs, William P., Hibshman, Priya S., Amparo, Amber M., Hennessey, Connor, Rees, Matthew G., Ronan, Melissa M., Roth, Jennifer A., Brodbeck, Jens, Tomassoni, Lorenzo, Bakir, Basil, Socci, Nicholas D., Herring, Laura E., Barker, Natalie K., Wang, Junning, Cleary, James M., Wolpin, Brian M., Chabot, John A., Kluger, Michael D., Manji, Gulam A., Tsai, Kenneth Y., Sekulic, Miroslav, Lagana, Stephen M., Califano, Andrea, Quintana, Elsa, Wang, Zhengping, Smith, Jacqueline A. M., Holderfield, Matthew, Wildes, David, Lowe, Scott W., Badgley, Michael A., Aguirre, Andrew J., Vonderheide, Robert H., Stanger, Ben Z., Baslan, Timour, Der, Channing J., Singh, Mallika, Olive, Kenneth P.

“…Broad-spectrum RAS inhibition has the potential to benefit roughly a quarter of human patients with cancer whose tumours are driven by RAS mutations 1 , 2 …”
Get full text

Author Correction: Tumour-selective activity of RAS-GTP inhibition in pancreatic cancer by Wasko, Urszula N., Jiang, Jingjing, Dalton, Tanner C., Curiel-Garcia, Alvaro, Edwards, A. Cole, Wang, Yingyun, Lee, Bianca, Orlen, Margo, Tian, Sha, Stalnecker, Clint A., Drizyte-Miller, Kristina, Menard, Marie, Dilly, Julien, Sastra, Stephen A., Palermo, Carmine F., Hasselluhn, Marie C., Decker-Farrell, Amanda R., Chang, Stephanie, Jiang, Lingyan, Wei, Xing, Yang, Yu C., Helland, Ciara, Courtney, Haley, Gindin, Yevgeniy, Muonio, Karl, Zhao, Ruiping, Kemp, Samantha B., Clendenin, Cynthia, Sor, Rina, Vostrejs, William P., Hibshman, Priya S., Amparo, Amber M., Hennessey, Connor, Rees, Matthew G., Ronan, Melissa M., Roth, Jennifer A., Brodbeck, Jens, Tomassoni, Lorenzo, Bakir, Basil, Socci, Nicholas D., Herring, Laura E., Barker, Natalie K., Wang, Junning, Cleary, James M., Wolpin, Brian M., Chabot, John A., Kluger, Michael D., Manji, Gulam A., Tsai, Kenneth Y., Sekulic, Miroslav, Lagana, Stephen M., Califano, Andrea, Quintana, Elsa, Wang, Zhengping, Smith, Jacqueline A. M., Holderfield, Matthew, Wildes, David, Lowe, Scott W., Badgley, Michael A., Aguirre, Andrew J., Vonderheide, Robert H., Stanger, Ben Z., Baslan, Timour, Der, Channing J., Singh, Mallika, Olive, Kenneth P.

Get full text

Tumor Explants Elucidate a Cascade of Paracrine SHH, WNT, and VEGF Signals Driving Pancreatic Cancer Angiosuppression by Hasselluhn, Marie C, Decker-Farrell, Amanda R, Vlahos, Lukas, Thomas, Dafydd H, Curiel-Garcia, Alvaro, Maurer, H Carlo, Wasko, Urszula N, Tomassoni, Lorenzo, Sastra, Stephen A, Palermo, Carmine F, Dalton, Tanner C, Ma, Alice, Li, Fangda, Tolosa, Ezequiel J, Hibshoosh, Hanina, Fernandez-Zapico, Martin E, Muir, Alexander, Califano, Andrea, Olive, Kenneth P

“…The sparse vascularity of pancreatic ductal adenocarcinoma (PDAC) presents a mystery: What prevents this aggressive malignancy from undergoing neoangiogenesis…”
Get more information

Abstract C60: Combination of MEK and autophagy inhibition promotes tumor regression in the KPC mouse model of pancreatic cancer by Wasko, Urszula N., Sastra, Stephen A., Palermo, Carmine F., Olive, Kenneth P.

“…Abstract Activating mutations of Kras are the main genetic drivers of pancreatic ductal adenocarcinoma (PDA) and are essential for its initiation and…”
Get full text

Abstract 1725: Preclinical evaluation of RM-042, an orally bioavailable inhibitor of GTP-RAS, in models of pancreatic ductal adenocarcinoma by Wasko, Urszula N., Sastra, Stephen A., Palermo, Carmine F., Wildes, David, Singh, Mallika, Olive, Kenneth P.

“…Abstract Approximately 95% of pancreatic ductal adenocarcinoma (PDAC) cases are driven by activating mutations in KRAS, accounting for over 45,000 deaths per…”
Get full text

Abstract B071: Preclinical evaluation of RM-042, an orally bioavailable inhibitor of GTP-RAS, in models of pancreatic ductal adenocarcinoma by Wasko, Urszula N., Sastra, Stephen A., Palermo, Carmine F., Wildes, David, Singh, Mallika, Olive, Kenneth P.

“…Abstract Approximately 95% of pancreatic ductal adenocarcinoma (PDAC) cases are driven by activating mutations in KRAS, accounting for over 45,000 deaths per…”
Get full text

Tumour-selective activity of RAS-GTP inhibition in pancreatic cancer by Wasko, Urszula N, Jiang, Jingjing, Dalton, Tanner C, Curiel-Garcia, Alvaro, Edwards, A Cole, Wang, Yingyun, Lee, Bianca, Orlen, Margo, Tian, Sha, Stalnecker, Clint A, Drizyte-Miller, Kristina, Menard, Marie, Dilly, Julien, Sastra, Stephen A, Palermo, Carmine F, Hasselluhn, Marie C, Decker-Farrell, Amanda R, Chang, Stephanie, Jiang, Lingyan, Wei, Xing, Yang, Yu C, Helland, Ciara, Courtney, Haley, Gindin, Yevgeniy, Muonio, Karl, Zhao, Ruiping, Kemp, Samantha B, Clendenin, Cynthia, Sor, Rina, Vostrejs, William P, Hibshman, Priya S, Amparo, Amber M, Hennessey, Connor, Rees, Matthew G, Ronan, Melissa M, Roth, Jennifer A, Brodbeck, Jens, Tomassoni, Lorenzo, Bakir, Basil, Socci, Nicholas D, Herring, Laura E, Barker, Natalie K, Wang, Junning, Cleary, James M, Wolpin, Brian M, Chabot, John A, Kluger, Michael D, Manji, Gulam A, Tsai, Kenneth Y, Sekulic, Miroslav, Lagana, Stephen M, Califano, Andrea, Quintana, Elsa, Wang, Zhengping, Smith, Jacqueline A M, Holderfield, Matthew, Wildes, David, Lowe, Scott W, Badgley, Michael A, Aguirre, Andrew J, Vonderheide, Robert H, Stanger, Ben Z, Baslan, Timour, Der, Channing J, Singh, Mallika, Olive, Kenneth P

“…Broad-spectrum RAS inhibition has the potential to benefit roughly a quarter of human patients with cancer whose tumours are driven by RAS mutations1,2…”
Get full text

Abstract 3874: Adaptive heterogeneity enables the survival of residual malignant PDAC cells in response to RAS-GTP inhibition by Tomassoni, Lorenzo, Wasko, Urszula N., Garcia, Alvaro C., Dalton, Tanner C., Laise, Pasquale, Sastra, Stephen A., Palermo, Carmine F., Califano, Andrea, Olive, Kenneth P.

“…Abstract More than 90% of human pancreatic ductal adenocarcinoma (PDAC) cases are driven by activating mutations in KRAS. RMC-7977 is a potent inhibitor of…”
Get full text

Abstract 934: RNA-based precision medicine predicts sensitivity to selinexor in select pancreatic ductal adenocarcinoma patients by Curiel-Garcia, Alvaro, Tomassoni, Lorenzo, Dalton, Tanner C., Decker-Farrell, Amanda R., Palermo, Carmine F., Ross, Daniel R., Sastra, Stephen A., Wasko, Urszula N., Goncalves, Isabel M., Mundi, Prabhot, Bakir, Basil S., Safyan, Rachael A., Hibshoosh, Hanina, Manji, Gulam A., Califano, Andrea, Olive, Kenneth P.

“…Abstract Sensitivity to therapeutic agents is impacted both by genetic heterogeneity between patients or among clones within a tumor and by heterogeneity of…”
Get full text

Abstract B101: Tumor-selective inhibition of active RAS in pancreatic ductal adenocarcinoma by Wasko, Urszula N., Jiang, Jingjing, Tomassoni, Lorenzo, Wang, Yingyun, Lee, Bianca, Orlen, Margo, Drizyte-Miller, Kristina, Menard, Marie, Dilly, Julien, Sastra, Steven A., Palermo, Carmine F., Chang, Stephanie, Aguirre, Andrew J., Der, Channing J., Vonderheide, Robert H., Stanger, Ben Z., Califano, Andrea, Singh, Mallika, Olive, Kenneth P.

“…Abstract RM-042 is a broad-spectrum inhibitor of the active (GTP-bound) form of KRAS, HRAS, and NRAS, with affinity for both mutant and wild type (WT) variants…”
Get full text

Abstract 1927: Resistance to RAS-GTP inhibition in models of pancreatic ductal adenocarcinoma arises downstream of RAS effectors by Wasko, Urszula N., Jiang, Jingjing, Wang, Yingyun, Tomassoni, Lorenzo, Jiang, Lingyan, Menard, Marie, Curiel-Garcia, Alvaro, Dalton, Tanner C., Orlen, Margo, Edwards, Cole, Stalnecker, Clint, Dilly, Julien, Chang, Stephanie, Sastra, Stephen A., Palermo, Carmine F., Baslan, Timour, Tian, Sha, Holderfield, Matthew, Quintana, Elsa, Wang, Zhengping, Smith, Jacqueline A., Califano, Andrea, Wildes, David, Aguirre, Andrew J., Vonderheide, Robert H., Stanger, Ben Z., Lowe, Scott W., Der, Channing J., Singh, Mallika, Olive, Kenneth P.

“…Abstract More than 90% of pancreatic ductal adenocarcinoma (PDAC) cases are driven by activating mutations in KRAS that drive it into an active, GTP-bound…”
Get full text

Internet Technology Makes Clinical Data Systems Technically and Economically Practical: Are They Politically Feasible? by Wasko, Norma H.

“…The creation of data systems capable of tracking health service inputs and outcomes were a major thrust of health reform. It proved neither technically nor…”
Get full text